在第二阶段试验显示对试验乳癌药物(NGC-Cap)有希望之后,制药公司股份猛涨了40%。 Processa Pharmaceuticals shares jumped 40% after a Phase 2 trial showed promise for its experimental breast cancer drug, NGC-Cap.

在2025年10月8日的下午交易中,Processa Pharmaceuticals股票幅近40%至0.51美元,在定期交易期间幅为29%,这是NGC-Cap的第二阶段试验进展所推动的,NGC-Cap是治疗晚期乳腺癌的新疗法. Processa Pharmaceuticals shares surged nearly 40% to $0.51 in after-hours trading on October 8, 2025, following a 29% gain during the regular session, driven by progress in a Phase 2 trial for NGC-Cap, a new treatment for advanced breast cancer. 全球有60至90名病人参加这一试验,相比之下,两剂NGC-Cap和Capecitabin的剂量为Capecitabine。 The trial, enrolling 60 to 90 patients globally, compares two doses of NGC-Cap to capecitabine. 尽管去年比去年下降了71%, 投资者对审判潜力的乐观情绪推动了这次集会, 尽管该公司仍处在临床阶段, 没有经过批准的产品。 Despite a 71% drop over the past year, investor optimism around the trial’s potential fueled the rally, though the company remains clinical-stage with no approved products.